BiotechTube

PA21

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis, Hyperphosphatemia

Trial Timeline

Apr 29, 2013 → Dec 3, 2013

NCT ID
NCT01850641

About PA21

PA21 is a phase 3 stage product being developed by Kissei Pharmaceutical for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT01850641. Target conditions include Hemodialysis, Hyperphosphatemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT01852682Phase 3Completed
NCT01850641Phase 3Completed
NCT01833494Phase 3Completed

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP7991Astellas PharmaPhase 1
33
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP1585Astellas PharmaPhase 2
52
Kiklin capsulesAstellas PharmaPre-clinical
23
DoravirineMerckApproved
85
BPS804 + PlaceboNovartisPhase 2
52
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
76
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
51
PA21Kissei PharmaceuticalPhase 3
76
[¹⁴C]EtelcalcetideAmgenPhase 1
32
Epoetin HospiraPfizerPhase 3
76
Epoetin HospiraPfizerPhase 3
76
sodium thiosulfateSanofiPre-clinical
22
EnoxaparineSanofiApproved
84
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
76

Other Products from Kissei Pharmaceutical

KAD-1229 + Placebo + InsulinApproved
84
Avacopan, prednisolone and rituximab + Prednisolone and rituximabApproved
84
KLH-2109 + LeuprorelinPhase 3
76
KAD-1229Phase 3
76
KUC-7483 + Placebo + TolterodinePhase 3
76